Cow, it may well have been Frost because i know that he still does own shares though he is not an active member of the board and he could be as patient as he'd like and I do know the smart guys always sell into strength.
This is going to move up and in very quick time. They are concentrating on sales and that's it. As far as the Lidocane patch, that is still an item but they are focusing on building their brand in wound care and making dollars. I love their singular focus on sales and marketing. Eventually, all these biotechs are going to have to prove themselves so it's nice to have ALQA that has the guns and the product and what i saw as a clear vision to sell bandages which is what I affectionately refer to ALQA as. They aren't sexy so they will have to prove it by the numbers which he stated as plain as day they are gearing up for.
To this day I still have never owned a stock that's held a gain as well as this. I think that people have figured out that ALQA could be a money machine with the best of breed in a growing segment of healthcare. They are about t to take the wound care industry head on with the help of CELG.
I wouldn't be the least bit surprised if either it closes even or better today, or it starts to move tomorrow because this company is focused on sales, sales and oh yeah, sales.
Hasn't what been over a year? The time that Cartwright's been here?
Good mangers do good things because they are good managers. This man has a solid reputation in the industry primarily built on diagnostic equipment. He was the father of the Omnyx system from GE and prior to starting Omnyx for GE, it was his responsibility, with a budget of 15 billion dollars to go out and assess and buy promising technologies because back then, GE grew thorough acquisition and not developing anything in house..
So Cartwright''s job was finding the best of the best diagnostic technologies from antwhere in the world with a budget that only a handful of people can personally claim to have had to work with..
Why does Cartwright park himself on GTHP's doorstep? It must be bad because you said it's been over a year now right?
You better email Cartwright and let him know before he makes a complete fool of himself.
Please be quiet unless you have something to add to the conversation besides estrogen..
If they won't let you borrow against it, you really technically can't short it. MM's can do so to keep orderly books and to correct imbalances , but there is no way you can call your broker and tell him to sell ONCS that you don't own. If there is, I'd like the link that tells me that I can.
Fur, the only way short selling can happen is against the box. That is where those warrants that were a part of that unit at .25 can be sold even though they have not been converted because they have the implication of ONCS ownership.
38 % short interest?? This MB is getting loonier and loonier. Still own ONCS but always question my ownership when I see the uninformed post such nonsense.....
Ed, if I'm not mistaken, they have announced the CC and are in a blackout until then which is why I tried to tamper your expectations about Friday and yesterday. Trust me, they will be fine, if only for the money they will save the healthcare systems of the countries that appreciate it. UK for instance. It is ultimately going to end up to be billion of dollars saved overall if and when this becomes a first line diagnostic tool.
Cow, I wish that I has a boatload more money because I am going to make money with either GTHP or ALQA. I cannot figure which one is going to make the move first. GTHP could be like a pressure cooker since it is trading at almost historic lows with all the positives going on, or we go with ALQA which has already tripled, but has the most sophisticated wound care products out there today.
With all the sophisticated bugs and germs out there today, preventing infection is going to be paramount. I still maintain that ALQA isn't sexy like cancer curing but it won't matter in the enbd because they are alrady selling and as Johnson spoke, a group of 40 sales reps were being trained in sales of the product mix.
Keep in mind, effectiveness of treatment is one thing. As I understand it, most ALQA products are incredibly easy to work with because they do not require adhesives which re sometimes the bane of healthcare providers.
This as Johnson stated has been pre approved and provided a billing code which was Biovances downfall when CELG was trying to market it.
I am curious about the need for treatment of wounds caused by violence, wars etc? We have heard a lot about ulcers from diabetes but unless I'm mistaken, not much said about old fashioned wound care. If I'm not mistaken, the advantage to using ALQA designed products is to reduce the possibility of infection, or am I just simply seeing one open wound the same as another open wound?
Adv Skin Wound Care. 2009 Apr;22(4):161-6. doi: 10.1097/01.ASW.0000305463.32800.32.
Pilot trial of biovance collagen-based wound covering for diabetic ulcers.
Letendre S1, LaPorta G, O'Donnell E, Dempsey J, Leonard K.
Diabetes mellitus affects more than 194 million people worldwide, resulting in nearly 40,000 limb amputations per year, secondary to infected ulcerations, peripheral neuropathy, and inadequate vascular status. Diabetic foot ulcers have an underlying metabolic etiology that contributes to a nonhealing ulcer. Biovance (Celgene Cellular Therapeutics, Morris, New Jersey) is a wound covering produced from decellularized, dehydrated human amniotic membrane. The purpose of this study was to determine healing rates for partial- and full-thickness diabetic foot ulcers treated with Biovance. The secondary objective was to determine time to complete wound closure and safety profile.
Open-label study of 14 patients with chronic nonhealing diabetic partial- or full-thickness ulcers.
Groups 1 and 2 (55.5% and 33.3%, respectively, comprising 60.1% of total participants) received a benefit from using Biovance wound covering, and there were no adverse reactions to the tissue.
Biovance helps decrease healing time for a population of patients with chronic nonhealing diabetic partial- or full-thickness foot ulcers. Randomized, controlled studies may be warranted.
May have read that wrong. Could someone of greater acumen explain this. One thing I noticed is that every deal that ALQA cuts is always very fair to ALQA and doesn't ever appear to sell the store out from under itself.
In fact, as I read it, some of them are taking hard earned cash and buying shares "at the market" I love it when a guy who sits in on the day to day operations owns shares for way more than I do.
People are deluding themselves that Cartwright has been sitting on his hands for the last 2 months. I'm sure that he's chosen the companies priorities with a lot more focus paid to where they're going everywhere else..
I am still astounded that the market still doesn't realize that this is a legitimate turn around situation.
Do you understand? The Company had debt that they converted into equity thereby increasing the share amount at probably very favorable terms to the debt holder. That alone should reinforce your opinion because people smarter than you and I took their first in line debt holdings and converted it to paper.
No one ever gets that many Kudo's with all the lunatics on this MB. Next people will be asking Mensa if their taking a dump the right way.
OOH Mensa, could you tell me how to fix the crack in my nuclear reactor? You seem so smart and all and I was just wondering if you could get this thing up to the proper gigawatts.
Tonoos, the stock is reacting the way it is because t doesn't know how to react. The itchiest of fingers will send this moving if the market likes what it hears.
Tonoos, I wonder what it would take to start a company from scratch that eventually has an approved diagnostic exam with virtually no competitors that was waiting for an audience with the FDA? More than 35 million?????
Strongest triple I've ever owned and people don't even know it's tripled.